TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The FDA cleared a wrist-worn device developed by Encora Therapeutics to help adults with essential tremor, according to MIT News. The technology began as a 2017 MIT student project; a clinical trial cited in the report found that 78% of participants reported benefits after 90 days of home use.
The U.S. Food and Drug Administration cleared Encora Therapeutics’ wrist-worn device to help adults with essential tremor, according to MIT News, nearly nine years after an early version was demonstrated in a Massachusetts Institute of Technology class. The clearance moves the student-developed technology from a classroom prototype toward use by people with a condition that causes involuntary shaking, often in the hands.
The device applies mechanical vibrations at the wrist. MIT News reports that the approach is intended to send sensory signals through the body that may affect the brain’s movement-control system and reduce tremors. The source describes the device as a treatment cleared to help adults with essential tremor; it does not provide the FDA’s detailed clearance documentation or specify the exact limits of the authorized use.
Encora’s development began in 2017, when a team in MIT’s 2.009 Product Engineering Processes class built a prototype. At a public presentation, a man identified as Michael, who had Parkinson’s disease, wore the device and drew a spiral with improved precision after switching it on. That demonstration involved Parkinson’s symptoms, while the reported FDA clearance is for adults with essential tremor—two distinct conditions.
The project later became Encora Therapeutics. Co-founder and vice president of strategy Daniel Carballo told MIT News that the company’s path involved years of hardware revisions and clinical testing. The report says that in one trial, 78% of patients reported benefits after 90 days of home use. It does not identify the trial’s participant count, the measure used to define benefit, or whether those results were the basis for the FDA decision.
A Wearable Option for Essential Tremor
The clearance gives adults with essential tremor access to a device-based approach that does not rely on medication alone. That matters because, according to Carballo’s account in MIT News, the company shifted its focus after learning that essential tremor represented a substantial unmet need and had seen less development activity than Parkinson’s disease. The source does not compare the device’s effectiveness with medicines or other treatments, so its place among available options remains a question for clinicians and patients.
The development also shows how a university engineering project can progress into a regulated medical product, but the classroom demonstration is not evidence by itself of clinical effectiveness. The reported trial result is encouraging as a patient-reported finding, yet it is not a substitute for fuller data on study design, safety, durability, or how many users benefit. The practical impact will depend on access, clinical guidance, and whether benefits hold up in broader use.
FDA cleared wrist tremor relief device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
From MIT Prototype to Encora
The project started in an MIT product-design class in 2017, when student Daniel Carballo proposed using vibration to influence signals involved in movement. The team selected the idea despite Carballo’s concerns that it was too ambitious for a single semester. Its first prototype was a basic assembly of a foam-core box, a Raspberry Pi computer, and wires, according to his recollection in MIT News.
After the demonstration drew requests from people seeking the device for relatives, some team members pursued commercialization with support from MIT entrepreneurial programs. They formed Encora Therapeutics in 2020. The company initially explored Parkinson’s disease and conducted a 2022 clinical trial with 20 people with Parkinson’s in collaboration with Mass General Brigham, the report says. It later turned toward essential tremor; the source says the company saw a greater unmet need in that area.
Michael’s onstage experience was a formative demonstration, not the FDA clearance event. The timeline in MIT News places the clearance in February 2026, about nine years after the class presentation. The two developments should be kept distinct: the first was a prototype demonstration involving a person with Parkinson’s, while the later clearance concerns helping adults with essential tremor.
““It’s been a long and difficult — very difficult — journey, but also very rewarding, especially when we get feedback from patients.””
— Daniel Carballo, Encora Therapeutics co-founder and vice president of strategy, quoted by MIT News
wearable essential tremor treatment device
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Clearance Details and Evidence
The MIT News account does not include the FDA’s clearance notice, the device’s brand name, its exact authorized-use wording, or details about who should not use it. It also does not explain whether clearance followed a particular FDA pathway or provide a full account of the evidence submitted to regulators. Those details are needed to understand the device’s approved scope and how it compares with other care options.
The reported 78% patient-reported benefit needs additional study context: the article does not state the trial size, comparison group, outcome scale, or how long any benefit lasted beyond 90 days. The source also does not provide adverse-event information, pricing, insurance coverage, or a timeline for broad availability. Readers should not interpret the reported percentage as proof that the device works for every person with essential tremor.
As an affiliate, we earn on qualifying purchases.
Availability and Clinical Guidance
The next practical milestones are the device’s commercial availability and the release of fuller information about its authorized use, evidence, safety, and cost. MIT News does not give a launch date or say where the device can be obtained. Patients and clinicians will need those details to determine whether it is an appropriate option for an individual’s symptoms and circumstances.
Further reporting should track any company announcement on distribution and any published clinical data that clarify the trial results. Until those details are available, the confirmed development is the FDA clearance reported in February 2026—not a claim that the device will work for all users or replace existing treatment.
As an affiliate, we earn on qualifying purchases.
Key Questions
What did the FDA clear?
According to MIT News, the FDA cleared Encora Therapeutics’ wrist-worn device to help adults with essential tremor. The report does not include the regulator’s detailed authorized-use language.
How does the device work?
The wearable applies mechanical vibrations at the wrist. The approach is intended to send sensory signals that may influence systems involved in movement, but the source does not provide a detailed technical explanation of the cleared device.
Is this a Parkinson’s treatment?
The original MIT demonstration involved a person with Parkinson’s disease, but the reported FDA clearance is for helping adults with essential tremor. The source does not report a clearance for Parkinson’s disease.
What does the 78% figure mean?
MIT News says that in one trial, 78% of patients reported benefits after 90 days of home use. The report does not give the trial size, comparison group, or the measure used to assess benefit, so the figure needs that context.
When can people get the device?
The source does not provide a sales date, pricing, or information about insurance coverage. Availability details remain unclear.
Source: hn
Columbus Day / Indigenous Peoples' Day Picks
long weekend sales
As an affiliate, we earn on qualifying purchases.
